| Literature DB >> 25886859 |
Ting-ting Qu1,2, Jian-cang Zhou3, Yan Jiang4, Ke-ren Shi5, Bin Li6, Ping Shen7, Ze-qing Wei8, Yun-song Yu9,10.
Abstract
BACKGROUND: Klebsiella pneumoniae has been the dominant pathogen for liver abscesses in several Asian countries. Although the prevalence of K. pneumoniae liver abscess (KLA) in mainland China is increasing recently, the clinical and microbiological characteristics of KLA in China have not been elucidated.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25886859 PMCID: PMC4381403 DOI: 10.1186/s12879-015-0899-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical characteristics of liver abscess in China
|
|
|
|---|---|
|
| |
| Male | 27(60.0%) |
| Female | 18(40.0%) |
|
| |
| mean age | 53.7 ± 11.2(18–73) |
| 18-49 | 14(31.1%) |
| 50-64 | 23(51.1%) |
| ≥65 | 8(17.8%) |
|
| |
| Diabetes mellitus | 22(48.9%) |
| Biliary tract diseases | 16(35.6%) |
| Abdominal surgery | 10(22.2%) |
| Immunosuppression* | 0 |
|
| 5(11.1%) |
|
| 14(31.1%) |
|
| |
| Single | 40(88.9%) |
| Multiple | 5(11.1%) |
| Right hepatic lobe | 35(77.9%) |
| Left hepatic lobe | 7(15.6%) |
| Both lobes | 3(6.7%) |
| Abscess size (cm) | |
| <5 | 5(11.1%) |
| 5-10 | 33(73.3%) |
| >10 | 7(15.6%) |
|
| |
| Metastatic infections | 14(31.1%) |
| Spontaneous bacterial peritonitis | 3(6.7%) |
| Pneumonia | 10(22.2%) |
| Endophthalmitis | 1(2.2%) |
| Septic shock | 3(6.7%) |
|
| |
| WBC (×109/L) | 11.9(7.0-28.1) |
| CRP (mg/L) | 106.9(28.8-311.0) |
|
| 0 |
*Immunosuppression may have been caused by the presence of human immunodeficiency virus infection, chemotherapy or radiotherapy within 1 month before the onset of illness, or glucocorticoid therapy (equivalent of 30 mg of prednisone per day) for 15 days before the onset of illness.
Microbiological characteristics of liver abscess
|
|
|
|---|---|
| Serotypes | |
| K1 | 31(68.9%) |
| K2 | 9(20%) |
| Non K1/K2 | 5(11.1%) |
| Virulence genes | |
| magA+ | 31(68.9%) |
| rmpA+ | 45(100.0%) |
| MLST | |
| ST23 | 26(57.8%) |
| Non-ST23 | 19(42.2%) |
| hvKP | 13(28.9%) |
| cKP | 32(71.1%) |
| ESBLs positive | 1(2.2%) |
|
| |
| Amikacin | 100% |
| Amoxicillin-clavulanate | 100% |
| Ampicillin | 0% |
| Ampicillin-sulbactam | 93.5% |
| Aztreonam | 100% |
| Cefoxitin | 95.7% |
| Cefuroxime | 95.7% |
| Cefepime | 97.8% |
| Cefotaxime | 97.8% |
| Ceftazidime | 100% |
| Ciprofloxacin | 97.8% |
| Gentamicin ,CN10 | 97.8% |
| Piperacillin | 76.1% |
| Piperacillin-tazobactam | 97.8% |
| Cefoperazone-sulbactam | 100% |
| Tetracycline | 93.5% |
| Minocycline | 93.5% |
| SMZ-TMP | 100% |
| Imipenem | 100% |
| Meropenem | 100% |
Figure 1PFGE analysis of the 26 ST23 strains.
Comparison of microbiological characteristics between ST23 and non-ST23 isolates from KLA
|
|
|
|
|
|---|---|---|---|
|
|
| ||
| Serotypes -no. (%) | |||
| K1 | 25(96.2%) | 6(31.6%) | <0.001 |
| K2 | 0(0.0%) | 9(47.4%) | <0.001 |
| Non K1/K2 | 1(3.8%) | 4(21.1%) | 0.146 |
| Virulence genes -no. (%) | |||
| magA+ | 25(96.2%) | 6(31.6%) | <0.001 |
| rmpA+ | 26(100.0%) | 19(100%) | 1 |
| hvKP -no. (%) | 6(23.1%) | 7(36.8%) | 0.341 |
| cKP -no. (%) | 20(76.9%) | 12(63.2%) | 0.341 |
| ESBLs positive -no. (%) | 1(3.8%) | 0(0.0%) | 0.387 |
Comparison of microbiological characteristics between hvKP and cKP isolates from KLA
|
|
|
|
|
|---|---|---|---|
|
|
| ||
| Serotypes -no. (%) | |||
| K1 | 7(53.8%) | 24(75%) | 0.286 |
| K2 | 6(46.2%) | 3(9.4%) | 0.011 |
| Non K1/K2 | 0(0.0%) | 5(15.6%) | 0.301 |
| Virulence genes -no. (%) | |||
|
| 7(53.8%) | 24(75%) | 0.286 |
|
| 13(100%) | 32(100%) | |
| ST23-no. (%) | 6(46.2%) | 20(62.5%) | 0.341 |
| Non-ST23 -no. (%) | 7(53.8%) | 12(37.5%) | 0.341 |
| ESBLs positive -no. (%) | 1(7.7%) | 0(0.0%) | 0.219 |
Comparison of clinical characteristics of KLA patients infected with different isolates
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| ||||
| Male sex | 17(65.4%) | 11(57.9%) | 0.757 | 8(61.5%) | 18(56.3%) | 1 | 17(54.8%) | 9(64.3%) | 0.746 |
| Age | 54.8 ± 11.9 | 52.3 ± 10.4 | 0.465 | 52.3 ± 8.7 | 54.3 ± 12.2 | 0.600 | 53.9 ± 12.5 | 53.2 ± 8.2 | 0.844 |
|
| |||||||||
| Diabetes mellitus | 13(50.0%) | 9(47.4%) | 1 | 4(30.8%) | 18(56.3%) | 0.189 | 16(50%) | 6(42.9%) | 0.749 |
| Biliary tract diseases | 8(30.8%) | 8(17.8%) | 0.534 | 4(30.8%) | 12(37.5%) | 0.743 | 8(25.8%) | 8(57.1%) | 0.053 |
| Abdominal surgery | 6(23.1%) | 4(21.1%) | 1 | 3(23.1%) | 7(21.9%) | 1 | 7(22.6%) | 3(21.4%) | 1 |
|
| 3(11.5%) | 2(5.3%) | 1 | 3(23.1%) | 2(6.3%) | 0.136 | 3(9.7%) | 2(14.3%) | 0.639 |
|
| 10(38.5%) | 4(21.1%) | 0.330 | 2(15.4%) | 12(37.5%) | 0.178 | 11(35.5%) | 3(21.4%) | 0.492 |
| Abscess size (diameter, cm) | 7.7 ± 2.4 | 7.4 ± 2.8 | 0.691 | 8.8 ± 2.4 | 7.1 ± 2.5 | 0.057 | 7.5 ± 2.3 | 7.9 ± 3.0 | 0.605 |
|
| |||||||||
| Metastatic infections | 10(38.5%) | 4(21.1%) | 0.330 | 5(38.5%) | 9(28.1%) | 0.486 | 11(35.5%) | 3(21.4%) | 0.492 |
| Spontaneous bacterial peritonitis | 3(11.5%) | 0(0.0%) | 1 | 0(0.0%) | 3(9.4%) | 0.546 | 3(9.7%) | 0(0.0%) | 0.541 |
| Pneumonia | 6(23.1%) | 4(21.1%) | 1 | 3(23.1%) | 7(21.9%) | 1 | 7(22.6%) | 3(21.4%) | 1 |
| Endophthalmitis | 1(3.8%) | 0(0.0%) | 1 | 0(0.0%) | 1(3.1%) | 1 | 1(3.2%) | 0(0.0%) | 1 |
| Septic shock | 3(11.5%) | 0(0.0%) | 0.258 | 2(15.4%) | 1(3.1%) | 0.196 | 3(9.7%) | 0(0.0%) | 0.541 |